PharmNovo is a Swedish pharma company based in Medicon Village, Lund. PharmNovo has developed a novel compound portfolio based on a new type of selective delta opioid receptor agonists (DORAs), intended to provide effective neuropathic pain relief without the adverse side effects of conventional opioids. The lead candidate, PN6047, is currently in the final stages of phase I studies and PharmNovo is preparing for phase 2 studies with PN6047 in chronic neuropathic pain and potentially other diseases of the nervous system.
Read morePN6047 is a unique substance based on research by PharmNovo’s founder Bengt von Mentzer. It is shown to be potent, safe, and effective and does not affect the receptors usually known to cause addiction to conventional opioids. It also lacks the usual unwanted side effects associated with other non-selective opioids. PN6047 will shortly be entering phase II proof-of-concept studies.
Read moreNeuropathic pain affects up to ten percent of the population in Europe and the United States, but the treatment of neuropathic pain is still a clearly unmet medical need. To date, there is no pain relief offered to these patients that is not associated with potentially severe side effects.
Read morePharmNovo will soon initiate a phase II proof of concept clinical study of the drug candidate PN6047 to show its effect on neuropathic pain conditions.
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read moreThe US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read moreOlof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read moreWe are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment. Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas." PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.
Read morePharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read moreOn May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read moreThe final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read moreBengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more